José Carlos Nicolau
A5000380712- Acute Myocardial Infarction Research
- Antiplatelet Therapy and Cardiovascular Diseases
- Cardiac Imaging and Diagnostics
- Coronary Interventions and Diagnostics
- Salivary Gland Disorders and Functions
- Atrial Fibrillation Management and Outcomes
- Lipoproteins and Cardiovascular Health
- Cardiovascular Function and Risk Factors
- Venous Thromboembolism Diagnosis and Management
- Heart Failure Treatment and Management
- Cardiac Health and Mental Health
- Cardiac Valve Diseases and Treatments
- Oral microbiology and periodontitis research
- Diabetes Treatment and Management
- Cardiac Structural Anomalies and Repair
- Health Systems, Economic Evaluations, Quality of Life
- Cancer, Hypoxia, and Metabolism
- Healthcare during COVID-19 Pandemic
- Laser Applications in Dentistry and Medicine
- COVID-19 Clinical Research Studies
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Cardiac pacing and defibrillation studies
- Cardiac Arrest and Resuscitation
- Dental Health and Care Utilization
- Adipokines, Inflammation, and Metabolic Diseases
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
2013-2025
Instituto do Coração
2013-2025
Universidade de São Paulo
2015-2024
Université Paris Cité
2024
Radboud University Medical Center
2024
Brigham and Women's Hospital
2013-2024
Beth Israel Deaconess Medical Center
2024
Radboud University Nijmegen
2024
Harvard University
2024
Hôpital Bichat-Claude-Bernard
2024
Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, inflammatory hypothesis atherothrombosis has remained unproved.We conducted a randomized, double-blind trial canakinumab, therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction high-sensitivity C-reactive protein level 2 mg or more per liter. The compared three doses canakinumab...
In patients with type 2 diabetes, inhibitors of sodium–glucose cotransporter (SGLT2) reduce the risk a first hospitalization for heart failure, possibly through glucose-independent mechanisms. More data are needed regarding effects SGLT2 in established failure and reduced ejection fraction, regardless presence or absence diabetes.
The potential benefit of dual antiplatelet therapy beyond 1 year after a myocardial infarction has not been established. We investigated the efficacy and safety ticagrelor, P2Y12 receptor antagonist with established an acute coronary syndrome, in this context.We randomly assigned, double-blind 1:1:1 fashion, 21,162 patients who had to 3 years earlier ticagrelor at dose 90 mg twice daily, 60 or placebo. All were receive low-dose aspirin followed for median 33 months. primary end point was...
Thrombin potently activates platelets through the protease-activated receptor PAR-1. Vorapaxar is a novel antiplatelet agent that selectively inhibits cellular actions of thrombin antagonism PAR-1.We randomly assigned 26,449 patients who had history myocardial infarction, ischemic stroke, or peripheral arterial disease to receive vorapaxar (2.5 mg daily) matching placebo and followed them for median 30 months. The primary efficacy end point was composite death from cardiovascular causes,...
The assessment of myocardial viability has been used to identify patients with coronary artery disease and left ventricular dysfunction in whom coronary-artery bypass grafting (CABG) will provide a survival benefit. However, the efficacy this approach is uncertain.In substudy who were enrolled randomized trial medical therapy or without CABG, we single-photon-emission computed tomography (SPECT), dobutamine echocardiography, both assess on basis prespecified thresholds.Among 1212 trial, 601...
The effect of intensified platelet inhibition for patients with unstable angina or myocardial infarction without ST-segment elevation who do not undergo revascularization has been delineated.In this double-blind, randomized trial, in a primary analysis involving 7243 under the age 75 years receiving aspirin, we evaluated up to 30 months treatment prasugrel (10 mg daily) versus clopidogrel (75 daily). In secondary 2083 older, 5 clopidogrel.At median follow-up 17 months, end point death from...
Vorapaxar is a new oral protease-activated-receptor 1 (PAR-1) antagonist that inhibits thrombin-induced platelet activation.In this multinational, double-blind, randomized trial, we compared vorapaxar with placebo in 12,944 patients who had acute coronary syndromes without ST-segment elevation. The primary end point was composite of death from cardiovascular causes, myocardial infarction, stroke, recurrent ischemia rehospitalization, or urgent revascularization.Follow-up the trial terminated...
The cholesteryl ester transfer protein inhibitor evacetrapib substantially raises the high-density lipoprotein (HDL) cholesterol level, reduces low-density (LDL) and enhances cellular efflux capacity. We sought to determine effect of on major adverse cardiovascular outcomes in patients with high-risk vascular disease.
Bococizumab is a humanized monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) and reduces levels of low-density lipoprotein (LDL) cholesterol. We sought to evaluate the efficacy bococizumab in patients at high cardiovascular risk.In two parallel, multinational trials with different entry criteria for LDL cholesterol levels, we randomly assigned 27,438 combined receive (at dose 150 mg) subcutaneously every 2 weeks or placebo. The primary end point was...
Thrombosis and inflammation may contribute to the risk of death complications among patients with coronavirus disease 2019 (Covid-19). We hypothesized that therapeutic-dose anticoagulation improve outcomes in noncritically ill who are hospitalized Covid-19.In this open-label, adaptive, multiplatform, controlled trial, we randomly assigned were Covid-19 not critically (which was defined as an absence critical care-level organ support at enrollment) receive pragmatically regimens either...
Elevated lipoprotein-associated phospholipase A2 activity promotes the development of vulnerable atherosclerotic plaques, and elevated plasma levels this enzyme are associated with an increased risk coronary events. Darapladib is a selective oral inhibitor A2.In double-blind trial, we randomly assigned 15,828 patients stable heart disease to receive either once-daily darapladib (at dose 160 mg) or placebo. The primary end point was composite cardiovascular death, myocardial infarction,...
Additional treatments are needed for heart failure with reduced ejection fraction (HFrEF). Sodium-glucose cotransporter 2 (SGLT2) inhibitors may be an effective treatment patients HFrEF, even those without diabetes.To evaluate the effects of dapagliflozin in HFrEF and diabetes.Exploratory analysis a phase 3 randomized trial conducted at 410 sites 20 countries. Patients New York Heart Association classification II to IV less than or equal 40% elevated plasma N-terminal pro B-type natriuretic...
Patients with diabetes mellitus (DM) have high platelet reactivity and are at increased risk of ischaemic events bleeding post-acute coronary syndromes (ACS). In the PLATelet inhibition patient Outcomes (PLATO) trial, ticagrelor reduced primary composite endpoint cardiovascular death, myocardial infarction, or stroke, but similar rates major compared clopidogrel. We aimed to investigate outcome vs. clopidogrel in patients DM poor glycaemic control. analysed pre-existing (n = 4662), including...
Background: Ezetimibe, when added to simvastatin, reduces cardiovascular events after acute coronary syndrome. We explored outcomes stratified by diabetes mellitus (DM). Methods: In IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial), 18 144 patients syndrome with low-density lipoprotein cholesterol 50 125 mg/dL were randomized 40 mg ezetimibe/simvastatin (E/S) or placebo/simvastatin. The primary composite end point was death, major events, and stroke. DM a...
Patients with stable coronary artery disease and diabetes mellitus who have not had a myocardial infarction or stroke are at high risk for cardiovascular events. Whether adding ticagrelor to aspirin improves outcomes in this population is unclear.
Goals of management in patients with heart failure and reduced ejection fraction include reducing death hospitalizations, improving health status (symptoms, physical function, quality life). In the DAPA-HF trial (Dapagliflozin Prevention Adverse-Outcomes Heart Failure), sodium-glucose cotransporter-2 inhibitor, dapagliflozin, improved symptoms fraction. this analysis, we examine effects dapagliflozin on a broad range outcomes, using Kansas City Cardiomyopathy Questionnaire (KCCQ).KCCQ was...
Background: Sodium glucose transporter-2 inhibitors reduce the risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes mellitus and a history atherosclerotic disease. Because their baseline risk, previous myocardial infarction (MI) may derive even greater benefit from sodium inhibitor therapy. Methods: DECLARE-TIMI 58 (Dapagliflozin Effect on Cardiovascular Events–Thrombolysis Myocardial Infarction 58) randomized 17 160 either established disease (n=6974) or...